Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Paula Cramer Julia von Tresckow Anna-Maria Fink Sandra Robrecht Adam Giza Eugen Tausch Lothar Müller Wolfgang Knauf Matthias Zingerle Othman Al-Sawaf Petra Langerbeins Kirsten Fischer Karl-Anton Kreuzer Michael Kneba Clemens-Martin Wendtner Stephan Stilgenbauer Barbara Eichhorst Michael Hallek

Am J Hematol

Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.

Published: June 2024

Download full-text PDF	Source
http://dx.doi.org/10.1002/ajh.27304	DOI Listing

Publication Analysis

Top Keywords

bendamustine obinutuzumab

obinutuzumab idelalisib

idelalisib chronic

chronic lymphocytic

lymphocytic leukemia

leukemia cll2-bcg

cll2-bcg final

final analysis

analysis multicenter

multicenter open-label

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!